Soon after, we established an anti-dyslipidemia peptide vaccine therapy targeting ANGPTL3 [Epitope 3, E3: EPKSRFAMLD (Fig. 1a)] using mouse models of obese dyslipidemia and familial hypercholesterolemia, as a potentially cost-effective therapeutic strategy against dyslipidemia and associated diseases such as fatty liver and atherosclerosis5. Here, ANGPTL3 is linked to metabolic syndrome.